Observational studyClinical rheumatology2026
Unveiling pleuropulmonary manifestations in systemic lupus erythematosus: a retrospective observational study from the Middle East.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prevalence of pleuropulmonary manifestations in a cohort of Jordanian patients with systemic lupus erythematosus and to identify associated factors.
methodsThis is a retrospective observational study in a tertiary care centre. A comprehensive review of the medical records of SLE patients was performed from 1 January 2000 to 31 December 2023 in order to obtain demographics, clinical data, laboratory, and radiological information.
resultsA total of 349 patients were included in the analysis. The average age was 43.3 ± 13.6 years, and most of this population were female (90.8%). Out of the total patients, 29.5% had at least one pleuropulmonary complication, and pleural effusion was found to be the most frequently reported, followed by pulmonary embolism (7.2%) and pulmonary hypertension (5.4%). Pulmonary function tests were found to have similar obstructive and restrictive patterns in 35.7% of patients. Among HRCT abnormalities, the most common was pleural effusion (33.8%), followed by ground-glass opacity (32.4%) and atelectatic bands (31.7%). Factors associated with the development of pleuropulmonary manifestations were positive lupus anticoagulant, positive anti-ANuA, and positive DCT.
conclusionAs many as 29.5% of the patients had pulmonary involvement. Pleural effusion was the most frequent pleuropulmonary manifestation. PFT showed similar percentages of obstructive and restrictive patterns. Factors associated with the development of pleuropulmonary manifestations were positive lupus anticoagulant, positive anti-ANuA, and positive DCT. This study is, to our knowledge, the first long-span Jordanian cohort to characterise pleuropulmonary involvement in SLE while identifying independent immunological predictors (lupus anticoagulant, Anti-ANuA, and DCT) and delineating a distinct distribution of lupus nephritis classes by pulmonary status.
Indexed as
Identifiers
41239079What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.